Attached files
file | filename |
---|---|
8-K - FORM 8-K - OMNI BIO PHARMACEUTICAL, INC. | c26736e8vk.htm |
EX-99.2 - EXHIBIT 99.2 - OMNI BIO PHARMACEUTICAL, INC. | c26736exv99w2.htm |
Exhibit 99.1
Omni Bio Announces Progress of BioMimetix Pharmaceutical
BioMimetix To Develop New Therapy for Cancer and Radiation Therapy
DENVER, CO, January 17, 2012 Omni Bio Pharmaceutical, Inc. (Omni Bio) (OMBP.ob), a
clinical-stage biopharmaceutical company, today announced a progress report of a new antioxidant
molecule being developed by BioMimetix Pharmaceutical, Inc. (BioMimetix), of which Omni Bio is
currently the largest shareholder.
BioMimetix is a recently formed biopharmaceutical company and intends to develop a new class of
compounds of higher potency from previous metalloporphyrin antioxidant mimetics for the treatment
of various diseases including radiation toxicity, a frequent side effect of cancer treatment using
radiation therapy. BioMimetix is the exclusive licensee of a 2010 issued patent owned by Duke
University directed to this new class of compounds. BioMimetix believes that its current
development compound, BMX-001, has significantly higher potency than earlier generation compounds.
BioMimetixs initial targeted indication for BMX-001 is in glioblastoma, an aggressive brain tumor.
Other targeted indications may include radiation therapy in the treatment of head and neck cancer
and the treatment of morphine tolerance.
Dr. James Crapo, chief executive officer of Omni Bio and BioMimetix, commented, We are pleased to
communicate that BioMimetix is progressing on plan in its first year of development of a new class
of mangano porphyrin (MP) antioxidant mimetics. BioMimetix was successfully launched in July 2011
with its first year capital needs adequately funded. It is proceeding through the GMP synthesis
phase of its new molecule, BMX-001, and its goal is to complete preclinical development to enable
an IND to be filed and the initiation of human studies in 2012.
About Omni Bio
Omni
Bio Pharmaceutical (www.omnibiopharma.com) is a clinical-stage biopharmaceutical company that
has licensed potential new indications for an existing FDA approved drug Alpha-1 antitrypsin
(AAT). Omni Bios lead development program has been funding research and a human clinical trial to
evaluate the effectiveness of AAT in the treatment of Type 1 diabetes. The Company also intends to
commence a new human clinical Type 1 diabetes trial as well as human clinical trial using AAT for
the treatment of bone marrow transplantation disease. Novel discoveries made at the University of
Colorado Denver indicate that AAT has the potential to address a variety of indications in the
areas of diabetes, transplant rejection and bacterial and viral disorders.
About BioMimetix
Omni Bio is a significant investor in BioMimetix, a recently formed biopharmaceutical corporation.
BioMimetix is the exclusive licensee of an issued patent owned by Duke University, and intends to
develop a new class of compounds for the treatment of various diseases including radiation toxicity
during the treatment of cancer using radiation therapy.
Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements that reflect
managements current views and expectations with respect to future events, including the operations
of BioMimetix. These forward-looking statements are not a guarantee of future events and are
subject to a number of risks and uncertainties, many of which are outside our control, which could
cause actual events to differ materially from those expressed or implied by the statements. These
risks and uncertainties are based on a number of factors, including but not limited to the business
risks disclosed in our SEC filings, especially the section entitled Risk Factors in our Annual
Report on Form 10-K for the fiscal year ended March 31, 2011 and the section entitled Risk
Factors in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011. We
undertake no obligation to publicly update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Omni Bio Pharmaceutical, Inc.
|
WestMountain Asset Management | |
Bob Ogden |
||
Chief Financial Officer Investor Relations
|
Steve Anderson Public Relations | |
(720) 488-4708
|
(970) 212-4770 | |
Email investor_relations@omnibiopharma.com
|
Email ir@westmountainam.com |
2